ReviewToxins2020
Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy.
Review in Toxins, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies.Frontiers in immunology · 2023Pooled it
- Trial
- Innovative technologies and future perspectives in tumor microbiomics.Science China. Life sciences · 2026Review
- Across the Social Network of the Gut: Bacterial, Fungal, and Viral Determinants of Checkpoint Inhibitor Efficacy and Toxicity.International journal of molecular sciences · 2026Review
- Attenuated Bacteria-Based Tumor Therapy: Clinical Application Risks, Marketing Approval Restrictions, and Coping Strategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Bridging cancer therapies: the role of magnetic nanoparticles in combination cancer therapy.Discover nano · 2026Review
- Microbiota in cancer: current understandings and future perspectives.Signal transduction and targeted therapy · 2026Review
- Spontaneous Remission of Acute Myeloid Leukemia With MutatedCase reports in hematology · 2026Article
- Review
- Polysaccharide Adjuvants as Innate Immune Trainers: Bridging Pattern Recognition Receptor (PRR) Activation and Metabolic Reprogramming for Synthetic Vaccine Design.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Review
- Advances in nanotechnology-enabled adjuvants for peptide-based cancer vaccines.Nano research · 2025Article
- Skin microbiome and dermatologic disorders.The Journal of clinical investigation · 2025Review
- Aptamer based immunotherapy: a potential solid tumor therapeutic.Frontiers in immunology · 2025Review
- Two homologous sequences of Grp78 and HSP70 represent tumor antigens shared with streptococcal superantigens in eliciting an antitumor immune response: an immunoinformatic investigation.Frontiers in immunology · 2025Article
- Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions.Frontiers in immunology · 2025Review
- Next-generation combination approaches for immune checkpoint therapy.Nature immunology · 2024Review
- The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives.Korean journal of clinical oncology · 2024Review
- Immunocyte membrane-derived biomimetic nano-drug delivery system: a pioneering platform for tumour immunotherapy.Acta pharmacologica Sinica · 2024Review
- Coley's Toxin to First Approved Therapeutic Vaccine-A Brief Historical Account in the Progression of Immunobiology-Based Cancer Treatment.Biomedicines · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The ability of the immune system to precisely target and eliminate aberrant or infected cells has long been studied in the field of infectious diseases. Attempts to define and exploit these potent immunological processes in the fight against cancer has been a longstanding effort dating back over 100 years to when Dr. William Coley purposefully infected cancer patients with a cocktail of heat-killed bacteria to stimulate anti-cancer immune processes. Although the field of cancer immunotherapy has been dotted with skepticism at times, the success of immune checkpoint inhibitors and recent FDA approvals of autologous cell therapies have pivoted immunotherapy to center stage as one of the most promising strategies to treat cancer. This review aims to summarize historic milestones throughout the field of cancer immunotherapy as well as highlight current and promising immunotherapies in development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.